Channel 7 shines a spotlight on Firebrick’s Phase 3 common cold trial for Nasodine

  17 May 2022

Firebrick Pharma’s Dr Peter Molloy and Dr Chris Rock from CMAX Clinical Research discuss with Channel 7 the start of our Phase 3 common cold trial for Nasodine® Nasal Spray. Adelaide is the first location for the trial, with sites in Victoria and South Africa to follow. If you live in South Australia or Victoria,…

Read More